United States: Ninth Circuit Rejects FCA Suit Alleging Medical Device Inaccuracies

In United States ex rel. Ruhe v. Masimo Corp., 640 Fed. App’x 666 (9th Cir. 2016), the Court of Appeals for the Ninth Circuit affirmed a grant of summary judgment for defendant Masimo Corporation, a medical device manufacturer. The relators in this False Claims Act (“FCA”) case had alleged that Masimo made fraudulent statements about the accuracy of the company’s pulse oximeter devices, rendering false any subsequent claims for payment to federal health care programs relating to the devices. The Ninth Circuit rejected those claims outright, holding that the relators had presented no evidence of false statements to customers or to the Food & Drug Administration (“FDA”), and no evidence of the required scienter.


Masimo manufactures and develops pulse oximeters, medical devices that measure blood characteristics. The products at issue in this litigation, known commercially as the Pronto devices, are oximeters capable of measuring both oxygen and total hemoglobin levels without drawing a blood sample. The Pronto devices are “point-of-care” tools that enable physicians to obtain real-time test results on-site without the need for laboratory tests. Such point-of-care devices are typically less accurate than laboratory tests, but carry the advantage of greater convenience and speed.

Between 2008 and 2011, the FDA cleared for marketing several iterations of the Pronto devices through the 510(k) premarket notification process. See 21 C.F.R. § 807 et seq.

The relators were Masimo sales representatives from 2009 until 2010, when they resigned allegedly over concerns about the Pronto devices’ performance. The relators reported their concerns in resignation letters to the company. Masimo responded by requesting additional information from the relators, conducting an internal investigation, and voluntarily notifying the FDA of the allegations. The relators then filed suit under the FCA.

On February 2, 2011, FDA investigators arrived unannounced at Masimo to perform an audit inspection. The FDA concluded its inspection without taking any enforcement action.

The relators alleged that Masimo knowingly made false or fraudulent statements relating to the Pronto devices by misrepresenting validation study data that Masimo submitted to the FDA during the 510(k) process and by failing to inform the FDA that the Pronto devices were less accurate in clinical use than in laboratory conditions. Indeed, the relators alleged that the Pronto devices were so clinically inaccurate as to be effectively worthless. Finally, the relators alleged that Masimo had knowingly provided false information to the American Medical Association (“AMA”) when requesting the creation of new billing codes for use by healthcare providers who bill for the Pronto devices.

Ninth Circuit Decision

The Ninth Circuit affirmed in whole the District Court’s grant of summary judgment in Masimo’s favor. The Court of Appeals held that Masimo had not misled the FDA about the Pronto devices’ accuracy, because the information Masimo submitted to the FDA “correctly stated the accuracy ranges at which the devices had been validated in laboratory testing conducted pursuant to” the FDA’s recommended standards, and the relators “pointed to no evidence undermining either the studies or tests results underpinning these accuracy specifications.” 640 Fed. App’x at 668.

While the relators had pointed to evidence of some customer feedback on the Pronto devices’ accuracy and internal Masimo discussions about improving accuracy, the District Court’s earlier decision held that Masimo had “in no way concealed or misrepresented the [FDA-cleared] accuracy specification for its devices” as determined through lab tests. 977 F. Supp. 2d 981, 994 (C.D. Cal. 2013). The Court of Appeals agreed, holding that “[i]solated complaints and anecdotal feedback about the accuracy of the Pronto Devices do not support an inference that Masimo committed knowing fraud by continuing to sell the devices with a stated FDA-clearance accuracy specification.” The Court of Appeals also rejected the “worthless services” allegation, holding that the company had provided “unrebutted testimony that the Pronto devices have clinical utility even with accuracy deviations beyond those cleared by the FDA.” 640 Fed. App’x at 669.

The Ninth Circuit summarily rejected the relator’s allegations that Masimo had knowingly provided false information to the AMA, noting that Masimo had provided the AMA with copies of its 510(k) clearance materials and FDA-cleared product manuals.

Finally, the Ninth Circuit held that even if Masimo had made some kind of false statement to customers concerning the Pronto devices’ accuracy, the relators had nonetheless failed to submit evidence establishing scienter as required by the FCA. That ruling endorsed the District Court’s earlier determination that the relators “presented no evidence that Masimo did not have a good faith belief that its devices were accurate.” 977 F. Supp. 2d at 995. In so holding, the Ninth Circuit adopted the reasoning of Masimo’s counsel during oral argument that an FCA suit is “not a referendum about how good are [the] devices” but rather the pertinent question is “[d]id we lie? Did we have scienter to mislead, to cause false claims against the government?”


The Ninth Circuit’s opinion makes clear that the FCA is not a mechanism for whistleblowers to second-guess the FDA’s regulatory decision-making process. When medical device manufacturers are transparent with the agency through the pre-market approval or clearance procedures, relators face a steep challenge to undermine the agency’s safety and efficacy determinations in subsequent civil litigation.

The decision is also a further reminder that the FCA’s scienter requirements have real bite. To survive summary judgment, relators must identify more than data trends or scientific inaccuracies; they must identify evidence that the defendant failed to act in good faith and, in short, that the defendant lied.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions